Simosky Johanna K, Stevens Karen E, Adler Lawrence E, Freedman Robert
Department of Pharmacology, University of Colorado Health Sciences Center, Campus Box C268-71, 4200 East 9th Avenue, Denver, CO 80262, USA.
Psychopharmacology (Berl). 2003 Feb;165(4):386-96. doi: 10.1007/s00213-002-1285-x. Epub 2002 Nov 30.
Insufficient inhibitory processing of the P50 auditory evoked potential (AEP) is observed in most schizophrenia patients and is not improved by typical antipsychotic drugs, such as haloperidol. This inhibitory processing deficit is associated with a subnormal level of hippocampal alpha7 nicotinic receptors (nAChRs), and drugs that activate these receptors normalize the deficit. The atypical antipsychotic clozapine also normalizes this deficit in schizophrenia patients, but by an unknown mechanism.
Similar to schizophrenia patients, DBA/2 mice spontaneously exhibit a deficit in inhibitory processing of the P20-N40 AEP, which is a rodent analogue of the human P50 AEP. The present study determined whether clozapine improved this deficit in DBA/2 mice, and by what mechanism.
Using a conditioning-testing paradigm with paired auditory stimuli to assess inhibitory P20-N40 AEP processing in DBA/2 mice, the effects of clozapine (0.1, 1, 3.33, or 10 mg/kg, i.p.) and haloperidol (1 mg/kg, i.p.) were assessed. The effect of clozapine (1 mg/kg) was assessed alone and after pre-administration of either alpha-bungarotoxin, an alpha7 nAChR antagonist, or dihydro-beta-erythroidine, an alpha4beta2 nAChR antagonist.
In a dose-dependent manner, clozapine improved the deficient inhibitory processing of the P20-N40 AEP normally exhibited by DBA/2 mice. Like alpha7 agonists, 1 mg/kg clozapine selectively increased the inhibition of the P20-N40 response to the second of paired auditory stimuli. The normalizing effect of 1 mg/kg clozapine was blocked by alpha-bungarotoxin, but not by dihydro-beta-erythroidine. Haloperidol did not improve DBA/2's deficient P20-N40 AEP processing.
Clozapine improved the deficient inhibitory processing of the P20-N40 AEP in DBA/2 mice, apparently through stimulation of alpha7 nicotinic receptors. This effect was not shared by the typical antipsychotic haloperidol.
多数精神分裂症患者的P50听觉诱发电位(AEP)抑制性处理不足,且典型抗精神病药物(如氟哌啶醇)无法改善这一情况。这种抑制性处理缺陷与海马α7烟碱型受体(nAChRs)水平低于正常有关,激活这些受体的药物可使该缺陷恢复正常。非典型抗精神病药物氯氮平也可使精神分裂症患者的这一缺陷恢复正常,但其机制尚不清楚。
与精神分裂症患者相似,DBA/2小鼠自发表现出P20-N40 AEP抑制性处理缺陷,这是人类P50 AEP的啮齿动物类似物。本研究确定氯氮平是否能改善DBA/2小鼠的这一缺陷,以及其机制是什么。
采用配对听觉刺激的条件测试范式评估DBA/2小鼠的P20-N40 AEP抑制性处理,评估氯氮平(0.1、1、3.33或10 mg/kg,腹腔注射)和氟哌啶醇(1 mg/kg,腹腔注射)的作用。单独评估氯氮平(1 mg/kg)的作用,以及在预先给予α7 nAChR拮抗剂α-银环蛇毒素或α4β2 nAChR拮抗剂二氢β-刺桐啶之后评估其作用。
氯氮平以剂量依赖性方式改善了DBA/2小鼠通常表现出的P20-N40 AEP抑制性处理缺陷。与α7激动剂一样,1 mg/kg氯氮平选择性增加了对配对听觉刺激中第二个刺激的P20-N40反应的抑制。1 mg/kg氯氮平的恢复正常作用被α-银环蛇毒素阻断,但未被二氢β-刺桐啶阻断。氟哌啶醇未改善DBA/2小鼠缺陷的P20-N40 AEP处理。
氯氮平改善了DBA/2小鼠P20-N40 AEP抑制性处理缺陷,显然是通过刺激α7烟碱型受体实现的。典型抗精神病药物氟哌啶醇没有这种作用。